#152159

Anti-Cytochrome P450 4V2 [M29-P3B10]

Cat. #152159

Anti-Cytochrome P450 4V2 [M29-P3B10]

Cat. #: 152159

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Cytochrome P450, family 4, subfamily V, polypeptide 2 (CYP4V2)

Class: Monoclonal

Application: ELISA ; IHC ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Ayham Alnabulsi

Institute: Vertebrate Antibodies Limited

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Cytochrome P450 4V2 [M29-P3B10]
  • Alternate name: Cytochrome P45; Family 4; Subfamily V; Polypeptide 2; Docosahexaenoic Acid Omega-Hydroxylase CYP4V2; CYP4AH1; BCD
  • Research fields: Cancer;Cell signaling and signal transduction;Metabolism;Tissue-specific biology
  • Clone: M29-P3B10
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; WB
  • Description: Cytochrome P450, family 4, subfamily V, polypeptide 2 (CYP4V2) encodes a member of the cytochrome P450 superfamily of enzymes that are a group of heme-thiolate monooxygenases. Cytochromes P450 catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. CYP4V2 catalyzes the omega-hydroxylation of medium-chain saturated fatty acids such as laurate, myristate and palmitate in an NADPH-dependent pathway. CYP4V2 may have a role in fatty acid and steroid metabolism in the eye and its mutations are associated with Bietti's crystalline dystrophy (BCD) and retinitis pigmentosas.
  • Immunogen: Peptide sequence KREELGLEGQ (amino acids 495 504)
  • Isotype: IgG1 kappa
  • Myeloma used: P3X63Ag8.653
  • Recommended controls: ELISA- Peptide immunogen; Western Blot- Human liver microsomes; IHC- Human liver

Target Details

  • Target: Cytochrome P450, family 4, subfamily V, polypeptide 2 (CYP4V2)
  • Tissue cell line specificity: ELISA- Peptide immunogen; Western Blot- Human liver microsomes; IHC- Human liver
  • Target background: Cytochrome P450, family 4, subfamily V, polypeptide 2 (CYP4V2) encodes a member of the cytochrome P450 superfamily of enzymes that are a group of heme-thiolate monooxygenases. Cytochromes P450 catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. CYP4V2 catalyzes the omega-hydroxylation of medium-chain saturated fatty acids such as laurate, myristate and palmitate in an NADPH-dependent pathway. CYP4V2 may have a role in fatty acid and steroid metabolism in the eye and its mutations are associated with Bietti's crystalline dystrophy (BCD) and retinitis pigmentosas.

Applications

  • Application: ELISA ; IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Alnabulsi et al. 2017. Br J Cancer. :. PMID: 28557975.
  • The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance.
  • Alnabulsi et al. 2016. Characterisation of Arachidonic Acid Metabolising Enzymes in Colorectal Cancer. J Pathol. 240 Suppl 1:S1-S48. PMID: 27747872
  • Nottingham Pathology 2016. 9th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 28 June - 1 July 2016.